- Company
- Bridion generic makers lose patent dispute after all
- by Kim, Jin-Gu Apr 20, 2020 06:34am
- Indicated for the reversal of neuromuscular blockade in people undergoing surgery, MSD’s Bridion (sugammadex) has successfully defended its patent rights. On Apr. 17, the Intellectual Property Trial and Appeal Board has ruled favorable for the original patentee MSD over a patent dispute with CTC BIO. A pharmaceutical market resear
- InterView
- New antibiotics need to be introduced
- by Eo, Yun-Ho Apr 20, 2020 06:32am
- Antibiotic resistance is a global health issue published by the World Health Organization (WHO). Multi-drug-resistant Gram-negative bacteria has increased worldwide and have become a serious problem in recent medical-related infections. In particular, the World Health Organization has designated Carbapenem-resistant Pseudomonas aeruginosa
- Company
- Half of multinational companies in Korea restructured 2019
- by An, Kyung-Jin Apr 20, 2020 06:30am
- Apparently, one out of two multinational pharmaceutical companies in Korea has downsized last year. The outcome contrasts with Korean pharmaceutical and bio companies that have increased employment in the same time, despite the worsened profitability. Analyzing audit reports submitted to the Financial Supervisory Service (FSS) on Apr. 16, 13
- Company
- Pfizer Korea Upjohn, last year's sales were ￦385.8 billion
- by Kim, Jin-Gu Apr 20, 2020 06:30am
- It was confirmed that the annual sales of Pfizer Korea Upjohn, which was split from Korea Pfizer Pharmaceuticals last year, amounted to ￦385.8 billion. Korea Pfizer Pharmaceuticals(￦395.7 billion) is not much different. Considering that Pfizer and the Pfizer Upjohn have a global sales ratio of 8 to 2, the sales share of Pfizer Upjohn in
- Policy
- The NHIS agreed the drug price negotiation rate to 95.5%.
- by Lee, Hye-Kyung Apr 20, 2020 06:30am
- The NHIS last year negotiated drug prices on 176 items, including new drugs. Of these, 96.5%, 168 items, completed the drug price negotiations, and 8 items had to be broken. Looking at the current status of the NHIS, which Dailypharm confirmed on the 7th, has negotiated the drug price in the past 6 years, a total of 870 drug price negotiation
- Policy
- Strong sanctions, to expel drugs through re-evaluation
- by Lee, Hye-Kyung Apr 17, 2020 06:22am
- It was suggested that strong sanctions to ban prescriptions as a way to expel drugs that have not been proven safe and effective through re-evaluation of benefits. It is necessary to take effective administrative measures beyond the preparation of a plan for drug withdrawal by the Minister of Health and Welfare, based on the National Health I
- Company
- Twice-delayed amid COVID-19 Cancer Committee rescheduled
- by Eo, Yun-Ho Apr 17, 2020 06:22am
- The Cancer Deliberation Committee’s meeting, postponed twice already, has been rescheduled. The Korean pharmaceutical industry sources reported the Health Insurance Review and Assessment Service (HIRA) has decided to resume the Cancer Deliberation Committee’s talks on expanding anticancer treatment coverage on Apr. 29. Amid COVID-1
- Company
- Merck's retirement allowance of ￦9.3 billion last year
- by An, Kyung-Jin Apr 17, 2020 06:21am
- Merck KGaA spent nearly 10 billion won last year as employee severance pay. With the sale of two types of hypertension and diabetes treatments, retirement payments related to restructuring jumped four times from the previous year. According to Merck KGaA's audit report submitted to the Financial Supervisory Service on the 14th, last year,
- Policy
- Domestic vaccine for COVID-19 developed within 2 years
- by Kim, Jung-Ju Apr 17, 2020 06:21am
- The government will immediately implement measures to support for the development of COVID-19 treatment and vaccines. The goal is to release antibody drugs as early as next year, blood plasma treatment within 2-3 months, and vaccines within 2 years. Tae-ho Yoon, the head of the quarantine, the Central Emergency Government Headquarters o
- Company
- Multinational companies show significant gap in performance
- by An, Kyung-Jin Apr 17, 2020 06:21am
- Multinational pharmaceutical companies in Korea showed drastically polarized performance last year. Their revenue fluctuated depending on how well the emerging driving forces took over the position of now-off-patent blockbuster drugs. Most of the companies had a drop in operating profit, but companies like Alcon, AbbVie and Sanofi-Aventis have s
